Current Drug Safety

Scope & Guideline

Advancing the Frontiers of Drug Safety Research

Introduction

Welcome to your portal for understanding Current Drug Safety, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1574-8863
PublisherBENTHAM SCIENCE PUBL
Support Open AccessNo
CountryUnited Arab Emirates
TypeJournal
Convergefrom 2006 to 2024
AbbreviationCURR DRUG SAF / Curr. Drug Saf.
Frequency3 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 294, BUSUM 1400 AG, NETHERLANDS

Aims and Scopes

Current Drug Safety focuses on the exploration, analysis, and reporting of drug safety profiles, adverse drug reactions (ADRs), and pharmacovigilance practices. The journal aims to provide a platform for sharing knowledge and findings related to drug safety, with an emphasis on clinical implications and real-world applications.
  1. Pharmacovigilance and Drug Safety Monitoring:
    The journal emphasizes the systematic monitoring of drug effects, including the identification and reporting of adverse drug reactions, ensuring patient safety in clinical settings.
  2. Case Reports and Literature Reviews:
    Current Drug Safety publishes detailed case reports and comprehensive literature reviews that highlight unique or severe drug reactions, offering insights into clinical management and therapeutic implications.
  3. Clinical Studies and Observational Research:
    The journal supports the publication of observational studies and cohort analyses that provide valuable data on the safety and efficacy of drugs in diverse patient populations.
  4. Drug Interactions and Treatment Protocols:
    Research focusing on drug-drug interactions, treatment efficacy, and safety assessments of drug combinations is a key area of interest, reflecting the complexities of modern pharmacotherapy.
  5. Public Health and Policy Implications:
    The journal discusses the broader implications of drug safety on public health and medication policies, aiming to inform healthcare practitioners and policymakers.
Current Drug Safety has seen a rise in several emerging themes that reflect the evolving landscape of drug safety research. These trends indicate a growing awareness of complex interactions and the need for comprehensive safety assessments in various contexts.
  1. Adverse Drug Reactions Related to COVID-19 Vaccines:
    Research related to the safety profiles and adverse effects of COVID-19 vaccines has gained significant prominence, highlighting the ongoing need for vigilance in vaccination programs.
  2. Drug-Drug Interactions in Polypharmacy:
    With the increasing prevalence of polypharmacy, there is a marked rise in studies addressing drug-drug interactions, especially in vulnerable populations such as the elderly.
  3. Patient Engagement in ADR Reporting:
    Emerging studies focus on enhancing patient engagement in reporting adverse drug reactions, utilizing novel approaches to improve pharmacovigilance practices.
  4. Long-term Safety Monitoring of Biologics and Biosimilars:
    There is a growing emphasis on the long-term safety and efficacy of biologic therapies and their biosimilars, particularly in chronic conditions like autoimmune diseases.
  5. Real-World Evidence and Observational Studies:
    The trend towards utilizing real-world evidence to assess drug safety and efficacy is increasing, reflecting a shift from controlled clinical trials to observational research that captures diverse patient experiences.

Declining or Waning

In recent years, certain themes within Current Drug Safety have shown a decline in focus or frequency of publication. This shift may reflect changing priorities in drug safety research or a saturation of previously explored topics.
  1. Traditional Pharmacology Studies:
    There has been a noticeable decrease in the publication of traditional pharmacology studies that primarily focus on drug mechanisms without addressing safety or adverse effects.
  2. General Drug Efficacy Studies:
    Research solely centered on the efficacy of medications, without a clear link to safety outcomes or adverse drug reactions, has decreased, signaling a shift towards a more safety-centric approach.
  3. Herbal and Alternative Medicine Studies:
    While still relevant, the focus on the safety profiles of herbal and alternative medications appears to be waning, perhaps due to the increasing emphasis on evidence-based practices in conventional pharmacotherapy.

Similar Journals

Expert Opinion On Drug Safety

Fostering Scholarly Dialogue on Drug Safety
Publisher: TAYLOR & FRANCIS LTDISSN: 1474-0338Frequency: 6 issues/year

Expert Opinion on Drug Safety is a prestigious academic journal dedicated to advancing knowledge in the fields of drug safety and pharmacology. Published by Taylor & Francis Ltd, this journal serves as an essential resource for researchers and professionals seeking to explore the complexities of drug interactions, adverse effects, and risk management. With an impressive impact factor and recognized as a Q1 journal in both the Medicine (Miscellaneous) and Pharmacology (Medical) categories, it ranks favorably at #78 out of 272 in Scopus, placing it in the 71st percentile among its peers. Operating under a rigorous peer-review process, the journal publishes original research, expert reviews, and opinion pieces that contribute to a deeper understanding of drug safety practices. While not an open access journal, it remains a vital platform for disseminating pivotal findings and fostering scholarly dialogue, ensuring that critical insights reach a global audience. With continuous publication from 2002 to 2024, Expert Opinion on Drug Safety is a key reference for anyone involved in pharmaceutical research, healthcare practice, or drug regulation.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Connecting Basic Science with Clinical Applications
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

BRITISH JOURNAL OF PHARMACOLOGY

Pioneering insights into drug mechanisms and therapeutic innovations.
Publisher: WILEYISSN: 0007-1188Frequency: 24 issues/year

British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.

BIOLOGICAL & PHARMACEUTICAL BULLETIN

Unlocking New Horizons in Pharmaceutical Research
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0918-6158Frequency: 12 issues/year

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

BMC Pharmacology & Toxicology

Fostering collaboration in pharmacology and toxicology.
Publisher: BMCISSN: Frequency: 1 issue/year

Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.

FARMACIA

Transforming Pharmaceutical Science into Practical Solutions.
Publisher: SOC STIINTE FARMACEUTICE ROMANIAISSN: 0014-8237Frequency: 6 issues/year

FARMACIA is a renowned academic journal published by the SOC STIINTE FARMACEUTICE ROMANIA, specializing in the field of pharmacology, toxicology, and pharmaceutics. With a rich history dating back to its initial publication years of 1945 to 1946, and ongoing contributions since 2008, the journal has established itself as a significant platform for disseminating cutting-edge research in the pharmaceutical sciences. Indexed in Scopus, it holds a commendable Q2 ranking in the Pharmacology, Toxicology and Pharmaceutics category, reflecting its importance in the field. The journal aims to foster knowledge sharing and innovation among researchers, professionals, and students alike, making it an essential resource for advancing pharmaceutical research. Although it does not currently offer Open Access, the content is accessible to a broad academic audience, ensuring valuable insights into current trends and discoveries in pharmacotherapy and drug development. For those seeking a deeper understanding of the evolving landscape of pharmaceutical sciences, FARMACIA provides a critical lens through which to explore and engage with the latest scientific advancements.

Safety

Empowering a safer tomorrow with open access insights.
Publisher: MDPIISSN: Frequency: 4 issues/year

Safety is a prestigious Open Access journal published by MDPI, based in Switzerland, dedicated to advancing research in the fields of public health, environmental safety, and occupational health. Since its inception in 2015, the journal has become a vital resource for researchers, practitioners, and policymakers, striving to foster innovative solutions to safety challenges in various sectors. With its rigorous peer-review process and a 2023 ranking in the Q2 category for Safety Research, as well as a notable presence in public health and environmental disciplines, Safety is well-respected in academic circles, holding a Scopus rank of 37/109 in Safety Research and 87/207 in Safety, Risk, Reliability, and Quality. The journal aims to disseminate high-quality research that not only reflects the latest advancements but also aids in developing practical strategies for risk management and safety improvement. Supported by an open-access model, Safety ensures that cutting-edge research is readily available to a global audience, fostering collaboration and knowledge sharing for a safer environment.

European Journal of Hospital Pharmacy

Empowering Practitioners with Cutting-edge Pharmacy Insights
Publisher: BMJ PUBLISHING GROUPISSN: 2047-9956Frequency: 6 issues/year

The European Journal of Hospital Pharmacy, published by the prestigious BMJ PUBLISHING GROUP, stands as a vital resource in the field of pharmacy, specifically focused on practices within hospital settings. With its ISSN 2047-9956 and E-ISSN 2047-9964, this journal provides an essential platform for researchers, practitioners, and students to disseminate and access high-quality research that influences clinical practice. Recognized for its significant impact, the journal has achieved a commendable Q2 ranking in both the Pharmacology, Toxicology and Pharmaceutics (miscellaneous) and Pharmacy categories according to Scopus, highlighting its status within the academic community. The journal is indexed among the top 18% in its category, showcasing innovative research and advancements in the field. While the European Journal of Hospital Pharmacy does not operate under an open-access model, its deep commitment to enhancing pharmaceutical care within European hospital settings remains undeterred. The journal also covers a converged period from 2010 to 2024, providing comprehensive insights into evolving practices and challenges. As a premier publication, it plays an essential role in education and professional development, making it indispensable for those involved in pharmacy and healthcare.

JOURNAL OF CLINICAL PHARMACOLOGY

Unveiling the Future of Drug Safety and Efficacy
Publisher: WILEYISSN: 0091-2700Frequency: 12 issues/year

Welcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.

CLINICAL THERAPEUTICS

Pioneering the future of drug development and clinical practice.
Publisher: ELSEVIERISSN: 0149-2918Frequency: 12 issues/year

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.